You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Opdivo/Yervoy improves survival in pleural mesothelioma

Bristol-Myers Squibb’s immunotherapy combination treatment Opdivo (nivolumab) plus Yervoy (ipilimumab) improved survival in patients with previously untreated, malignant pleural mesothelioma (MPM).